Clinical Trial Update: The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial studying a combination of Bifidobacterium longum 35624 and 1714 strains in adults with irritable bowel syndrome, with exploratory in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety
• Irritable Bowel Syndrome
• Major Depressive Disorder

Drugs mentioned

• Bifidobacterium longum 35624 (BB536) and 1714 strains combination (Bifidobacterium longum 35624; Bifidobacterium longum 1714)

Snippet

Sponsor: PrecisionBiotics Group Ltd. | Conditions: IBS - Irritable Bowel Syndrome, Depression, Anxiety | Phase 1, Phase 2 | Status: COMPLETED